ISIN
FR0012432516
Ticker
POXEL
Sector
Sub-Industry
Country
France
Year Founded
2009
Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders. Poxel has clinical and earlier-stage programs from its adenosine monophosphate-activated protein kinase (AMPK) activator and deuterium-modified thiazolidinedione (dTZD) platforms targeting chronic and rare metabolic diseases. Poxel’s first-in-class lead product, TWYMEEG® (Imeglimin), that targets mitochondrial dysfunction, has been approved for the treatment of type 2 diabetes in Japan.
53
Worldwide
Date | Trading entity / Person | Association | Trade type | Volume |
---|---|---|---|---|
29.01.2024 | None | Other | Buy | EUR 0.00 |
FR0012432516
Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.